The effectiveness of non-nucleoside dual therapy in “naive” HIV patients

Abstract

INTRODUCTION: Non-nucleoside antiretroviral therapy (ART) regimens are used to reduce the risk of adverse events associated with the use of nucleoside reverse transcriptase inhibitors. One of these treatment regimens is dolutegravir, dovavirin (DTG, DOR) dual therapy. MATERIALS AND METHODS: The study included 152 ''naive''HIV patients no clinical manifestations, 79 received DTG, DOR (G1), 73 – DTG, tenofovir (TDF), emtricitabine (FTC) (G2). Viral load (VL) and immunological parameters (CD4+, CD8+, CD4+/CD8+ ratio) were determined in patients before the start of treatment, after 48 weeks of ART. The efficacy of treatment was determined by the average level of VL, the proportion of patients with undetectable VL and the proportion of patients with an increase in CD4+ more than 50 cl/µl. The assessment was carried out using t-test for independent samples, the differences were significant at p 0.05. RESULTS: Groups were comparable in age, gender, VL and immunological parameters (Table).48 weeks after the start of ART, average level of VL in G1 and G2 was 0.54 and 0.69 lg copies/ml, respectively (p =0.757). Undetectable VL in G1 was 92.4% of patients, in G2 – 90.4% of patients (p =0.882), increase in CD4+ more than 50 cl/µl in G1 was 98.7% of patients, in G2 – 98.6% (p=0.512) of patients. CONCLUSIONS: DTG, DOR dual therapy was comparable with DTG, TDF, FTC triple therapy: it allowed to achieve an undetectable VL in 92.4% of patients and an increase in CD4+ more than 50 cl/µl in 98.7% of patients after 48 weeks of ART.

Keywords

• HIV infection
• non-nucleoside dual therapy
• efficacy